Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.48 |
| ▸ | KIF11 | P52732 | 3/20 | 0.46 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564581 | 0.91 | KIF11 (0.55) | LRRK2KIF11CA9PTGS2PTGS1 | |
| SCHEMBL3559273 | 0.91 | LRRK2 (0.53) | LRRK2KIF11PTGES2CA9PTGS2 | |
| SCHEMBL3556916 | 0.90 | NR1H2 (0.46) | KIF11PTGES2PTGS2PTGS1SYK | |
| SCHEMBL3569629 | 0.89 | KIF11 (0.39) | LRRK2KIF11PTGES2PTGS2CHRNA7 | |
| SCHEMBL3562756 | 0.89 | SYK (0.42) | LRRK2KIF11PTGES2SYKCHRNA7 | |
| SCHEMBL3563882 | 0.88 | ALDH1A1 (0.45) | LRRK2KIF11PTGES2 | |
| SCHEMBL3568740 | 0.88 | LRRK2 (0.45) | LRRK2KIF11PTGES2CA9PTGS2 | |
| SCHEMBL3569720 | 0.87 | NR1H2 (0.48) | KIF11PTGES2MAOASYKCA1 | |
| SCHEMBL3571723 | 0.87 | LRRK2 (0.47) | LRRK2KIF11PTGES2CA9PTGS2 | |
| SCHEMBL3566731 | 0.87 | PTGS2 (0.46) | LRRK2KIF11PTGES2CA9PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001849-B1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | claimed |
| EP-2468727-A1 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | claimed |
| US-8183262-B2 | Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | claimed |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GATTI MCARTHUR SILVIA | 2009-12-24 | — | — | US | claimed |
| EP-2001849-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | claimed |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | claimed |
| WO-2007110337-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | claimed |
| US-20190343839-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | HOFFMANN-LA ROCHE INC. (US) | 2019-11-14 | — | — | US | disclosed |
| US-20170173022-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF AUTISTIC DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173022-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF AUTISTIC DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170035767-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170035767-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-09 | — | — | US | disclosed |
| WO-2015162076-A2 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-29 | — | — | WO | disclosed |
| EP-2468727-A1 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8183262-B2 | Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-7642264-B2 | Phenyl-substituted pyrimidine derivatives as mGluR antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GATTI MCARTHUR SILVIA | 2009-12-24 | — | — | US | disclosed |
| EP-2001849-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007110337-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035767-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | GRM2, GRM3, GRIK2 | LRRK2 1402/4885KIF11 2171/4885PTGES2 439/4885 |
| US-20190343839-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES | GRM2, GRM3, GRM5 | LRRK2 1497/4885KIF11 2471/4885PTGES2 304/4885 |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | P2RX2, P2RY2, P2RX1 | LRRK2 414/4885KIF11 3845/4885PTGES2 773/4885 |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GRM2, GRM1, GRM3 | LRRK2 558/4885KIF11 3339/4885PTGES2 562/4885 |
| US-20170173022-A1 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF AUTISTIC DISORDERS | GRM2, GRM3, GRM5 | LRRK2 1065/4885KIF11 2336/4885PTGES2 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.